0001104659-22-080215 - Verrica Pharmaceuticals

About Us
Our
Medicines
- YCANTH
Product
Candidates
Investors &
Media
Careers

Menu

About Us
Our
Medicines
- YCANTH
Product
Candidates
Investors &
Media
Careers

Breaking News:
Verrica announced the approval of YCANTH™ (cantharidin) topical solution 0.7%

Document Details

Form: SC 13D
Filing Date: July 15, 2022
Document Date: July 15, 2022
Form Description: Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Group: Other
Company: Verrica Pharmaceuticals

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

About Us

Our Company
Leadership
Compliance
Contact
Medical Education Grants

Our Medicines

YCANTH

Product Candidates

Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications

Investors & Media

Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection

Careers

Terms of Use
Privacy Policy
Patent Notices

Twitter Linkedin-in Facebook-f

© 2023 Verrica Pharmaceuticals.

BREAKING NEWS:

Verrica announced the approval of YCANTH (cantharidin) topical solution

Please see Important Safety Informa tion and full Prescribing Information